Potential Use of Lu 177 Vipivotide Tetraxetan in Non-VISION Prostate Cancer Settings

Video

Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
Related Content